Kidney cancer follow-up after surgery is based on recurrence risk rather than one identical scan schedule for everyone. Follow-up may include clinical review, kidney-function and blood-pressure monitoring, and periodic imaging of the chest and abdomen. Small low-risk tumours usually need less intensive imaging than high-risk cancers. Follow-up also protects the remaining kidney: renal function, cardiovascular risk and chronic kidney disease matter even when there is no evidence of cancer. Your final pathology, stage, grade, subtype and surgical margin help determine the surveillance plan.

What is follow-up looking for?

• Local recurrence near the operated kidney
• A new tumour in the opposite kidney
• Spread to lungs, bones, liver or other organs
• Postoperative complications
• Decline in kidney function
• Blood pressure and cardiovascular risk

How often are scans needed?

Guideline-based surveillance is risk-adapted. Higher-risk tumours are generally scanned more often in the first few years, while low-risk disease may have wider intervals. CT commonly includes chest and abdomen; MRI of the abdomen may substitute when appropriate. The exact schedule should be documented after final pathology.

Blood tests and kidney protection

Creatinine/eGFR should be followed, especially after radical nephrectomy or in people with diabetes, hypertension or pre-existing kidney disease. A nephrology opinion can be useful when kidney function is significantly reduced or declining. Avoiding unnecessary nephrotoxic medicines and controlling blood pressure are part of long-term survivorship.

What symptoms should be reported between visits?

• New visible blood in urine
• Persistent unexplained weight loss or loss of appetite
• New persistent bone pain
• Persistent cough or breathlessness
• New flank or abdominal swelling/pain
• Neurological symptoms such as weakness, severe headache or seizures

When can follow-up stop?

There is no universal finish date. Some low-risk patients may eventually stop routine oncological imaging after discussion of age, other illnesses and recurrence risk, while high-risk disease may justify longer surveillance. Functional kidney follow-up may continue even after cancer imaging has ended.

Follow-up should match recurrence risk

A small low-grade pT1 tumour removed completely does not need the same imaging intensity as a pT3 high-grade clear-cell RCC. Follow-up schedules use stage, grade, histology and patient factors to balance early detection against unnecessary CT radiation, contrast exposure and cost. Kidney function and cardiovascular risk also remain relevant after nephrectomy.

What a new lung nodule or tiny node means

Surveillance scans frequently find small abnormalities unrelated to recurrence. A single indeterminate lung nodule is not automatically metastatic kidney cancer. Comparison with prior scans, growth over time and the pattern of disease matter. This is one reason keeping earlier images—not only reports—is useful.

When surveillance changes into treatment planning

A confirmed isolated recurrence may sometimes be treated locally with surgery or radiotherapy, while multiple or rapidly progressive metastases usually shift the discussion toward systemic therapy. The pattern, pace and symptoms of recurrence matter; treatment is not triggered solely because one scan contains the word “lesion.”

What a sensible surveillance plan should contain

A useful follow-up plan states which scan is needed, how often, for how many years, and what blood tests are being monitored. It should also explain how surveillance changes with stage and grade rather than using the same schedule for everyone. Keep the original operation note, pathology and baseline postoperative scan; when a tiny lung nodule or lymph node appears later, comparison with prior imaging often prevents unnecessary alarm or unnecessary treatment.

When to seek earlier medical review

Do not wait until the next routine visit for persistent haematuria, new focal bone pain, progressive cough/breathlessness, unexplained weight loss or a new abnormality reported on outside imaging. Bring the actual scan for comparison whenever possible.

What to bring to your consultation

• Original pathology and operation summary
• Previous and latest surveillance scans/images
• Creatinine/eGFR trend
• Any systemic-treatment records

Questions to ask your doctor

• What recurrence-risk group determines my scan schedule?
• Which scans and blood tests can safely become less frequent over time?
• What finding would make you restart active treatment?

FAQs

Related reading

• Kidney Cancer: Symptoms and Treatment
• CT Scan for Kidney Cancer
• Partial Nephrectomy Explained
• Radical Nephrectomy Explained
• Urologist in Latur

References

• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/diagnostic-evaluation
• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Disease Management https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/disease-management
• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Follow-up in RCC https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/followup-in-rcc
• National Cancer Institute. Renal Cell Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq